According to a recent LinkedIn post from Infinitus Systems, the company is highlighting findings from its new report, “The State of Specialty Drug Access 2026.” The post notes that in the analyzed patient pool, 95.7% retained their insurance coverage and 98.7% of required specialty drugs remained on formulary this year.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Despite these indicators of coverage stability, the post raises the question of why therapy abandonment persists among patients. Infinitus Systems attributes the report’s insights to real-world benefit verification data captured by its AI agents, emphasizing that the dataset is based on payor responses rather than surveys or modeled projections.
The post suggests that the report provides granular breakdowns by state and therapeutic area, positioning it as a data asset for stakeholders seeking to understand barriers to specialty drug access. For investors, this focus on ground-truth payer data may signal an effort by Infinitus Systems to differentiate its technology platform and analytics capabilities in a complex reimbursement and access landscape.
If widely adopted by manufacturers, payers, or providers, such data products could support more informed market access strategies and potentially drive incremental revenue opportunities for Infinitus Systems. At the same time, the emphasis on persistent therapy abandonment highlights ongoing friction in specialty pharmaceutical access, a structural challenge that could sustain demand for workflow automation and verification tools like those the company appears to be promoting.